Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지

한국 영아에서 eIPV의 면역원성과 안정성

Immunogenicity and safety of enhanced-inactivated poliovaccine(eIPV) in healthy Korean infants

  • 김정수 (전북대학교 의과대학 소아과학교실) ;
  • 홍영진 (인하대학교 의과대학 소아과학교실) ;
  • 김종덕 (원광대학교 의과대학 소아과학교실) ;
  • 장영택 (전주예수병원 소아과) ;
  • 강진한 (가톨릭대학교 의과대학 소아과학교실)
  • Kim, Jung Soo (Department of Pediatrics, Chonbuk National University Medical School) ;
  • Hong, Young Jin (Department of Pediatrics, College of Medicine, Inha University) ;
  • Kim, Jong Duk (Department of Pediatrics, Scool of Medicine, Wonkwang University) ;
  • Jang, Young Taek (Department of Pediatrics, Jeonju Presbyterian Medical Center) ;
  • Kang, Jin Han (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
  • 투고 : 2005.11.04
  • 심사 : 2006.06.09
  • 발행 : 2006.08.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

목 적 : 폴리오 백신은 OPV와 IPV가 있으며 모두 탁월한 예방효과를 보여 이제는 지구상에서의 폴리오 근절을 기대하게 되었다. 그러나 OPV 백신바이러스의 유전자 변형과 이로 인한 마비환자 발생이 알려지면서 폴리오 근절을 위해서는 반드시 OPV를 중단하고 IPV를 사용하게 되었다. 우리나라에서도 2002년 이후 새로운 eIPV 사용이 추천되었으며 2005년말 부터는 eIPV만을 사용하고 있다. 본 연구는 최근 국내에 도입된 eIPV의 면역원성과 안정성을 확인 하고자 하였다. 방 법 : 생후 2개월 된 건강한 영아 81명을 대상으로 폴리오백신을 2개월 간격으로 3회 접종한 후 혈청 내 중화항체가를 측정하였다. 폴리오 백신은 Imvax $Polio^{(R)}$(Aventis Pasteur, Lyon, France)로 단독 또는 DTaP와 B형 간염 또는 Hib 백신을 동시에 접종하였다. 면역원성은 접종 전 및 3회 접종 1개월 후에 혈청 내 중화항체가를 측정하였다. eIPV의 안전성은 접종 후 30분 동안 병원에서 조기 이상반응을 관찰하였으며 접종 후 3일간은 보호자에 의해 국소 및 전신 반응을 관찰하였다. 결 과 : 81명 중 79명이 성공적으로 연구를 마쳤다. eIPV 접종 전 및 3회 접종 후 혈청 내 중화 항체가(GMT)는 폴리오바이러스 1형은 접종 전 4.1에서 접종 후 1,531로 증가하였으며, 2형은 접종 전 7.7에서 접종 후 834로 증가하였고, 3형은 접종 전 3.3 에서 접종 후 846으로 증가하였다. 3회 접종 후 중화 항체가의 양전율은 1, 2, 3형 모두 100%를 보였다. 이상 반응으로는 발적(3.4%) 동통(2.5%) 등의 국소반응과 보챔(9.7%), 기면(5.5%), 식욕부진(4.6%), 발열(4.2%) 등의 전신반응이 있었으며 모두 해열제 사용 등 간단한 처치로 회복되었다. 결 론 : 최근 국내에 도입된 eIPV(Imovax $Polio^{(R)}$)는 면역원성이 높고 안전성이 확인되어 안심하고 사용할 수 있을 것이다.

Purpose : We evaluated the immunogenicity and safety of eIPV(Imovax $Polio^{(R)}$) in a group of healthy Korean infants on a three-dose primary vaccination. Methods : Eighty one healthy infants aged 8-10 weeks were enrolled, and 79(male 42, female 37) completed the study. Three doses of eIPV were injected intramuscularly at 2, 4 and 6 months of age as of primary vaccination. Most subjects received concomitant vaccines such as DTaP and/or Hib at 2, 4, and 6 months of age. Immediate reactions were monitored for 30 minutes after each injection. Local and systemic events were recorded for 72 hours following each immunization by parents/guardians. Poliovirus specific neutralizing antibodies were measured using enzyme immuno-assay (EIA) at prior to and 1 month after the third dose. An antibody titer of 1:8 or higher was considered seroprotective. Geometric mean titers(GMTs) to each poliovirus type antigen were also measured. Results : One month after the third dose of eIPV, all infants(100 percent) were seroprotective. The geometric mean titers(GMTs) were 1,532(95 percent CI : 1,312-1,788) in type 1 and 835(95 percent CI : 684-1,018) in type 2 and 846(95 percent CI : 692-1,035) in type 3. Overall, local reactions were observed in 10 percent of infants and systemic reactions in 26.2 percent of infants. All reactions were observed within 3 days after vaccination and resolved without treatment. Conclusion : eIPV(Imovax $Polio^{(R)}$) is a well-tolerated and highly immunogenic vaccine. It can be administered either alone or simultaneously with other routine vaccines to Korean infants.

키워드

과제정보

연구 과제 주관 기관 : 아벤티스 파스퇴르 코리아(주)

참고문헌

  1. Simoes EAF. Polioviruses. In : Behrman RE, Kliegman RM, Jensen HB, editors. Nelson Textbook of Pediatrics. 17th ed. Philadelphia : WB Saunders Co, 2004:1036-42
  2. Cherry JD. Enterovirus and Parechoviruses. In : Feigin RD, Cherry JD, Demmler GJ, Kaplan SL, editors. Textbook of Pediatric Infectious Diseases. 5th ed. Philadelphia : WB Saunders Co, 2004: 1984-2041
  3. Plotkin SA, Vidor E. Poliovirus vaccine-inactivated. In : Plotkin SA, Orestein WA, Offit PA. Vaccines. 4th ed. Philadelphia : WB Saunders Co, 2004:625-49
  4. Sutter RW, Kew OM, Cochi SL. Poliovirus vaccine-live attenuated. In : Plotkin SA, Orestein WA, Offit PA. Vaccines. 4th ed. Philadelphia : Saunders, 2004:651-705
  5. WHO. Global eradication of poliomyelitis by the year 2000. In Forty-first World Health Assembly, Geneva, May 2-13, 1988. Geneva, WHO 1988:26
  6. Korea Centers for Disease Control and Prevention. Outbreak of Polio, Yemen and Indonesia, 2000. Communicable Diseases Monthly Report. Seoul, Korea Centers for Disease Control and Prevention 2005;16:110
  7. Sabin AB. Commentary on report on oral poliomyelitis vaccine. JAMA 1964;190:52-5 https://doi.org/10.1001/jama.1964.03070140058008
  8. Horstmann DM, Emons J, Gimpel L, Subrahmanyan T, Riodan JT. Enterovirus surveillance following a community- wide oral poliovirus vaccination program : A seven year study. Am J Epidemiol 1973:97;173-86 https://doi.org/10.1093/oxfordjournals.aje.a121498
  9. Sutter RW, Prevots DR. Vaccine-associated paralytic poliomyelitis among immunodeficient persons. Infect Med 1994; 11:426-38
  10. WHO Collaborative Study Group. The relationship between persisting spinal paralysis and poliomyelitis vaccine(oral) : results of a WHO enquiry. Bull World Health Organ 1976; 53:319-31
  11. WHO Collaborative Study Group. The relationship between persisting spinal paralysis and poliomyelitis vaccine : results of a ten-year enquiry. Bull World Health Organ 1982; 60:231-42
  12. The Committee of Infectious Diseases, Immunization Program, 5th ed, The Korean Soc of Pediar, Kwangmoon Co., Seoul, 2002:75-87
  13. Advisory Committee on Immunization Program, Epidemiology and preventiion of vaccine-preventable disease, Korea Center for Disease Control and Prevention, 2005: 123-37
  14. Albrecht P, Steenis G, Wezel L, Salk J. Standardization of poliovirus neutralizing antibody tests. Rev Inf Dis 1984:6(2 Suppl):540S-544S https://doi.org/10.1093/clinids/6.Supplement_2.S540
  15. Centers for Disease Control and Prevention. Progress toward global poliomyelitis eradication, 1985-1994. MMWR 1995;44:273-5
  16. Strebel PM, Sutter RW, Cochi SL, Biellik RJ, Brink EW, Kew OM, et al. Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis 1992;14: 568-79 https://doi.org/10.1093/clinids/14.2.568
  17. Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States : Introduction of a sequential vaccination followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices. MMWR 1997;46:1-25
  18. McBean AM, Thoms ML, Albrecht P, Cuthie JC, Bernier R. Serologic response to oral polio vaccine and enhancedpotency inactivated polio vaccines. Am J Epidemiol 1988;128:615-28 https://doi.org/10.1093/oxfordjournals.aje.a115009
  19. The National Committee of Certification of Poliomyelitis Eradication in the Republic of Korea. National Documentation for Certification of Poliomyelitis Eradication, The Ministry of Health and Welfare, Seoul, 2000:2-60
  20. Kim JS. Evaluation of Poliomyelitis vaccination. In : Ministry of Health and Welfare, Korea. Evaluation of immunization system in Korea. Ministry of Health and Welfare, Seoul, 1995:99-113
  21. Kim SJ, Kim SH, Jee YM, Kim JS. Vaccine-associated paralytic poliomyelitis : A case report of flaccid monoparesis after OPV. J Korean Med Sci 2007;22 In press
  22. Montagnon BJ. Polio and rabies vaccines produced in continuous cell lines: A reality for Vero cell line. Dev Biol Stand 1989;70:27-47
  23. Robertson SE, Traverso HP, Drucker JA, Rovira EZ, Fabre-Teste B, Sow A, et al. Clinical efficacy of a new enhanced-potency, inactivated poliovirus vaccine. Lancet 1988;23;897-9 https://doi.org/10.1016/S0140-6736(00)43704-9
  24. Faden H, Modlin JF, Thoms ML, McBean AM, Ferdon MB, Ogra PL. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood : systemic and local immune responses. J Infect Dis 1990;162:1291-7 https://doi.org/10.1093/infdis/162.6.1291
  25. Susan CA, Jones A, Faden H, Ferden MB, Kwong MS, Ogra PL. Systemic and local responses to enhanced-potency inactivated poliovirus vaccine in premature and term infants. J Pediatr 1992;120:686-9 https://doi.org/10.1016/S0022-3476(05)80228-8
  26. Halsey NA, Blatter M, Bader G. Safety and immunogenicity of a combination DPT/IPV vaccine administered to infants in a dual-chamber syringe : final report. Swiftwater, PA, Connaught Laboratories. 1994. In reference 3
  27. Nirmal S, Cherian T, Samuel BU, Rajasingh J, Raghupathy P, John TJ. Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine. Vaccine 1998;16:928-31 https://doi.org/10.1016/S0264-410X(97)00293-4
  28. Grenier B, Hamza B, Biron G, Xueref C, Viarme F, Roumiantzeff M. Seroimmunity following vaccination in infants by an inactivated poliovirus vaccine prepared on Vero cells. Rev Inf Dis 1984;6(2 Suppl):545S-547S https://doi.org/10.1093/clinids/6.Supplement_2.S545
  29. Ruuskanen O, Salmi TT, Stevik M, Lapinleimu K. Inactivated poliovaccine : adverse reactions and antibody responses. Acta Paediatr Scand 1980;6:397-401